leadf
logo-loader
TSX:CRDL OTCQX:CRTPF

Cardiol Therapeutics

Receive alerts
Market:
TSX
Market Cap:
$98.35 m
Price
3.00 CAD
Change
0.67%
52 weeks high
5.00
52 weeks low
1.87

In brief

Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) is a clinical-stage biotechnology company focused on developing therapies for inflammatory heart disease. The Company has received approval from the U.S. FDA for its Investigational New Drug application to commence a Phase II/III clinical trial to investigate its lead product, CardiolRx™, in hospitalized COVID-19 patients with a history of, or risk factors for, cardiovascular disease. CardiolRx™ is a pharmaceutically produced, cGMP certified, THC free (<10 ppm) oral cannabidiol formulation. Cardiol is also planning a Phase 2 trial in acute myocarditis. The Company recently launched Cortalex™, www.cortalex.com, the first THC-free extra-strength formulation of cannabidiol oil available across Canada online at Medical Cannabis by Shoppers.

Snapshot

The company is expecting significant growth in the second half of 2020 as it moves to launch its pharmaceutical cannabidiol formulation in Canada